285 related articles for article (PubMed ID: 28639409)
1. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
Bender C; Enk A; Gutzmer R; Hassel JC
Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
4. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.
Johnson DB; Bao R; Ancell KK; Daniels AB; Wallace D; Sosman JA; Luke JJ
J Natl Compr Canc Netw; 2019 Feb; 17(2):114-117. PubMed ID: 30787124
[No Abstract] [Full Text] [Related]
5. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
6. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV; Amaral T; Kähler KC; Heinzerling L; Hassel JC; Meissner M; Kreuzberg N; Loquai C; Reinhardt L; Utikal J; Dabrowski E; Gesierich A; Pföhler C; Terheyden P; Thoms KM; Zimmer L; Eigentler TK; Kirchberger MC; Stege HM; Meier F; Schlaak M; Berking C
J Immunother Cancer; 2019 Nov; 7(1):299. PubMed ID: 31722735
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
10. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
12. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
13. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M; Mellor JD; McArthur G; Kee D
Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.
Namikawa K; Takahashi A; Mori T; Tsutsumida A; Suzuki S; Motoi N; Jinnai S; Kage Y; Mizuta H; Muto Y; Nakano E; Yamazaki N
Melanoma Res; 2020 Feb; 30(1):76-84. PubMed ID: 31095037
[TBL] [Abstract][Full Text] [Related]
16. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
17. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
19. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study.
Tacar SY; Selcukbiricik F; Yilmaz M; Erturk K; Murat Sarici A; Gulturk I; Ayhan M; Tural D
Melanoma Res; 2021 Oct; 31(5):449-455. PubMed ID: 34039945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
